Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Marberry

Orthopaedic Surgery Kirksville, MO Medical Doctor

NPI 1417995523 CMS profile 830629

800 W Jefferson St Fl 1, Kirksville, MO 63501

Open in the dashboard

General payments

$21,357

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Marberry of Kirksville, MO is reported in the CMS Open Payments database as having received $21,357 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,152 19
2024 General $2,152 8
2023 General $1,403 15
2022 General $1,730 5
2021 General $8,206 38
2020 General $156 5
2019 General $4,558 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Marberry
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Kevin Marberry were reported at $3,152. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Kevin Marberry Orthopaedic Surgery median Middle half National median
2019 $4,558 $644 $140–$2,844 $163
2020 $156 $312 $75–$1,860 $114
2021 $8,206 $520 $117–$2,495 $132
2022 $1,730 $598 $128–$2,731 $149
2023 $1,403 $461 $128–$2,264 $160
2024 $2,152 $497 $134–$2,475 $164
2025 $3,152 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $9,284 53 payments
  2. Elite Orthopedics, LLC $8,573 38 payments
  3. Smith+Nephew, Inc. $2,148 7 payments
  4. Stryker Corporation $804 9 payments
  5. Zimmer Biomet Holdings, Inc. $307 2 payments
  6. Wright Medical Technology, Inc. $139 1 payment
  7. DePuy Synthes Sales Inc. $71 2 payments
  8. Vertex Pharmaceuticals Incorporated $17 1 payment
  9. bioMerieux $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,436 29 payments
  2. Education $9,146 9 payments
  3. Food and Beverage $2,776 76 payments
Products named General payments · program years 2019–2025
  1. JOURNEY $1,631 5 payments
  2. OR3O Dual Mobility $1,631 5 payments
  3. RI Hip Navigation $1,631 5 payments
  4. JOURNEY II Recon Knees $1,631 5 payments
  5. LEGION Revision $1,631 5 payments
  6. ACCOLADE $599 1 payment
  7. JOURNEY II Recon Knees $492 1 payment
  8. JOURNEY II Recon Knees $492 1 payment
  9. ROSA $307 2 payments
  10. CARTIVA $139 1 payment
  11. Other $327 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

93

Median for Orthopedic Surgery: 203

Drug cost

$363

Median for Orthopedic Surgery: $1,433

Branded share of claims

43%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $178
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $93
Meloxicam Generic 41 $66
Tramadol Hcl Generic 12 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$123,753

Of which drugs: $5,228

Medicare patients

296

Average age 74

Services billed

3,375

185 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Chronic kidney disease 29%
Atrial fibrillation 24%
COPD 24%
Depression 24%
Ischemic heart disease 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 15 74 $4,247
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 75 540 $363

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record